This is the first comprehensive evaluation of the mitochondrial genome in the National Cancer Institute (NCI) 60 panel. The data from this study will be a valuable tool for integrating mitochondrial genomics with other data derived from the NCI 60 panel.
Eric Kaldjian, chief scientific officer of Transgenomic, said: “Tens of thousands of compounds have been tested against the NCI 60 cell lines in the NCI’s pharmacological database of cancer drugs. This collaboration makes it possible to test whether in vitro responses to anti-cancer agents are linked to alterations in the mitochondrial genome and can be detected with our sensitive mutation detection technology.”